Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension

Journal of Cardiovascular Pharmacology

Volumn 33, Issue 4, 1999, Pages 652-658

  Surdacki, Andrzej ^a,d   Nowicki, Michał ^b   Sandmann, Joerg ^c   Tsikas, Dimitrios ^c   Boeger, Rainer H ^c   Bode Boeger, Stephanie M ^c   Kruszelnicka Kwiatkowska, Olga ^a   Kokot, Franciszek ^b   Dubiel, Jacek S ^a   Froelich, Juergen C ^c  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b UNIVERSITY OF SILESIA   (Poland)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d NONE   (Poland)

Author keywords

Asymmetric dimethylarginine; Dyslipidemia; Essential hypertension; Insulin resistance; Nitric oxide

Indexed keywords

INSULIN; N(G),N(G) DIMETHYLARGININE; NITRATE; NITRIC OXIDE; NITRITE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG URINE LEVEL; DYSLIPIDEMIA; ESSENTIAL HYPERTENSION; HUMAN; INSULIN RESISTANCE; MALE; PRIORITY JOURNAL;

ADULT; ARGININE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; INSULIN RESISTANCE; MALE; NITRIC OXIDE;

EID: 0032912757     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199904000-00020     Document Type: Article

References (68)

1. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;286:373-6.
2. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002-11.
3. Vallance P, Calver J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 1989;2:997-1000.
4. Ignarro LJ, Buga GM, Wood KS. Activation of purified guanylate cyclase by endothelium-derived relaxing factor from intrapulmonary artery and vein: stimulation by acetylcholine, bradykinin and arachidonic acid. J Pharmacol Exp Ther 1986;237:893-900.
5. Panza JA, Casino PA, Kilcoyne CM, Quyyumi AA. Role od endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation 1993;87:1468-74.
6. G-monomethyl-L-arginine in patients with hypertension: the nitric oxide dilator mechanism appears abnormal. J Hypertens 1992;10:1025-31.
7. Quyyumi AA, Mulcahy D, Andrews NP, Husain S, Panza JA, Cannon RO III. Coronary vascular nitric oxide activity in hypertension and hypercholesterolemia: comparison of acetylcholine and substance P. Circulation 1997;95:104-10.
8. Tschudi MR, Mesaros S, Luescher TF, Malinski T. Direct in situ measurement of nitric oxide in mesenteric resistance arteries: increased decomposition by superoxide in hypertension. Hypertension 1996;27:32-5.
9. Nava E, Noll G, Luescher TF. Increased activity of constitutive nitric oxide synthase in cardiac endothelium in spontaneous hypertension. Hypertension 1995;91:2310-3.
10. Rubanyi GM, Vanhoutte PM. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am J Physiol 1986;250:H822-7.
11. Parik T, Allikmets A, Teesalu R, Zilmer M. Oxidative stress and hyperinsulinemia in essential hypertension: different facets of increased risk. J Hypertens 1996;14:407-10.
12. Garcia CE, Kilcoyne CE, Cardillo C, Cannon RO III, Quyyumi AA, Panza JA. Effect of copper-zinc superoxide dismutase on endothelium-dependent vasodilation in patients with essential hypertension. Hypertension 1995;26(pt 1):863-8.
13. Butler AR, Flitney FW, Williams DLH. NO, nitrosonium ions, nitroxide ions, nitrosothiols and iron-nitrosyls in biology: a chemist's perspective. Trends Pharmacol Sci 1995;16:18-22.
14. Jungersten L, Edlund A, Petersson AS, Wennmalm A. Plasma nitrate as an index of nitric oxide formation in man: analyses of kinetics and confounding factors. Clin Physiol 1996;16:369-79.
15. Takahashi H, Nakanishi T, Nishimura M, Tanaka H, Yoshimura M. Measurements of serum levels of nitrate ions in men and women: implications of endothelium-derived relaxing factor in blood pressure regulation and atherosclerosis. J Cardiovasc Pharmacol 1992; 20(suppl 12):S214-6.
16. Bode-Boeger SM, Boeger RH, Creutzig A, et al. L-Arginine infusion decreases peripheral arterial resistance and inhibits platelet aggregation in healthy subjects. Clin Sci 1994;87:303-10.
17. - excretion as an indicator of nitric oxide formation in vivo during oral administration of L-arginine and L-NAME in rats. Clin Exp Pharmacol Physiol 1996;23:11-5.
18. Grabowski PS, England AJ, Dykhuizen R, et al. Elevated nitric oxide production in rheumatoid arthritis: detection using the fasting urinary nitrate:creatinine ratio. Arthritis Rheum 1996;39:643-7.
19. Forte P, Copland M, Smith LM, Milne E, Sutherland J, Benjamin N. Basal nitric oxide synthesis in essential hypertension. Lancet 1997;349:837-42.
20. Boeger RH, Bode-Boeger SM, Thiele W, Junker W, Alexander K, Froelich JC. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 1997;95:2068-74.
21. Node K, Kitakaze M, Yoshikawa H, Kosaka H, Hori M. Reduced plasma concentrations of nitrogen oxide in individuals with essential hypertension. Hypertension 1997;30(pt 1):405-8.
22. Boeger RH, Bode-Boeger SM, Szuba A, Tsao PS, Chan JR, Cooke JP. Asymmetric dimethylarginine: a novel risk factor for endothelial dysfunction [Abstract]. Circulation 1997;96(suppl I):I-32.
23. Sagnella GA, Markandu ND, Onipinla AK, Chelliah R, Singer DR, MacGregor GA. Plasma and urinary nitrate in essential hypertension. J Hum Hypertens 1997;11:587-8.
24. Bonnardeaux A, Nadaud S, Charru A, Jeunemaitre X, Corvol P, Soubrier F. Lack of evidence for linkage of the endothelial cell nitric synthase gene in essential hypertension. Circulation 1995;91: 96-102.
25. Ferrannini E, Buzzigoli G, Bonadonna R, et al. Insulin resistance in essential hypertension. N Engl J Med 1987;317:350-7.
26. Garg A. Insulin resistance in the pathogenesis of dyslipidemia. Diabetes Care 1996;19:387-100.
27. Higashi Y, Oshima T, Sasaki N, et al. Relationship between insulin resistance and endothelium-dependent vascular relaxation in patients with essential hypertension. Hypertension 1997;29(pt 2):280-5.
28. Zeiher AM, Schaechinger V, Hohnloser SH, Saurbrier B, Just H. Coronary atherosclerotic wall thickening and vascular reactivity in humans: elevated high-density lipoproteins ameliorate abnormal vasoconstriction in early atherosclerosis. Circulation 1994;89: 2525-32.
29. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572-5.
30. Fickling SA, Williams D, Vallance P, Nussey SS, Whitley GStJ. Plasma concentrations of endogenous inhibitor of nitric oxide synthesis in normal pregnancy and pre-eclampsia. Lancet 1993;342: 242-3.
31. Goonasekera CDA, Rees DD, Woolard P, Frend A, Shah V, Dillon MJ. Nitric oxide synthase inhibitors and hypertension in children and adolescents. J Hypertens 1997;15:901-9.
32. Bode-Boeger SM, Boeger RH, Schroeder EP, Froelich JC. Exercise increases systemic nitric oxide production in men. J Cardiovasc Risk 1994;1:173-8.
33. 15N-labeled analogs. J Chromatogr B 1994;661: 185-91.
34. Tsikas D, Gutzki FM, Rossa S, et al. Measurement of nitrite and nitrate in biological fluids by gas chromatography-mass spectrometry and by the Griess assay: problems with the Griess assay - solutions by gas chromatography-mass spectrometry. Anal Biochem 1997;244: 208-20.
35. Bode-Boeger SM, Boeger RH, Kienke S, Junker W, Froelich JC. Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits. Biochem Biophys Res Commun 1996;219:598-603.
36. Tsikas D, Junker W, Froelich JC. Determination of dimethylated arginines in human plasma by high-performance liquid chromatography. J Chromatogr B 1998;705:174-6.
37. DeFronzo RA, Tobin J, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-23.
38. Haenni A, Berglund L, Reneland R, Andersson P-E, Lind L, Lithell H. The alterations in insulin sensitivity during angiotensin converting enzyme inhibitor treatment are related to changes in the calcium/magnesium balance. Am J Hypertens 1997;10:145-51.
39. Kharitonov SA, Logan-Sinclair RB, Busset CM, Shineboume EA. Peak expiratory nitric oxide differences in men and women: relation to the menstrual cycle. Heart 1994;72:243-5.
40. Node K, Kitakaze M, Yoshikawa H, Kosaka H, Hori M. Reversible reduction in plasma concentration of nitric oxide induced by cigarette smoking in young adults. Am J Cardiol 1997;79:1538-11.
41. Nestel PJ, Yamashita T, Sasahara T, et al. Control of the forearm microcirculation: interactions with measures of obesity and noradrenaline kinetics. Clin Sci 1998;95:203-12.
42. Tack CJ, Ong MK, Lutterman JA, Smits P. Insulin-induced vasodilation and endothelial function in obesity/insulin resistance: effects of troglitazone. Diabetologia 1998;41:569-76.
43. Cadwgan TM, Benjamin N. Evidence of altered platelet NO synthesis in essential hypertension. J Hypertens 1993;11:417-20.
44. Pedrinelli R, Giampietro O, Carmassi F, et al. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet 1994;344: 14-8.
45. Avogaro A, Piarulli F, Valerio A, et al. Forearm nitric oxide balance, vascular relaxation, and glucose metabolism in NIDDM patients. Diabetes 1997;46:1040-6.
46. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. J Clin Invest 1996;97:2601-10.
47. Utriainen T, Meakimattila S, Virkamaeki A, Bergholm R, Yki-Jaervinen H. Dissociation between insulin sensitivity of glucose uptake and endothelial function in normal subjects. Diabetologia 1996;39:1477-82.
48. Petrie JR, Ueda S, Webb DJ, Elliott HL, Connell JMC. Endothelial nitric oxide production and insulin sensitivity: a physiological link with implications for pathogenesis of cardiovascular disease. Circulation 1996;93:1331-3.
49. Kamide K, Nagano M, Nakano N, et al. Insulin resistance and cardiovascular complications in patients with essential hypertension. Am J Hypertens 1996;9(12 Pt 1):1165-71.
50. Natali A, Taddei S, Quinones-Galvan A, et al. Insulin sensitivity, vascular reactivity, and clamp-induced vasodilation in essential hypertension. Circulation 1997;96:849-55.
51. Mackness MI, Durrington PN. HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis 1995;115:243-53.
52. Matsuda Y, Hirata K, Inoue N, et al. High density lipoprotein reverses inhibitory effect of oxidized low density lipoprotein on endothelium-dependent arterial relaxation. Circ Res 1993;72:1103-9.
53. Nishikimi T, Yoshihara F, Morimoto A, et al. Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertension 1996;28:22-30.
54. MacAllister RJ, Rambausek MH, Vallance P, Williams D, Hoffmann K-H, Ritz E. Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure. Nephrol Dial Transplant 1996;11:2449-52.
55. G-dimethyl-L-arginine, a potential endogenous nitric oxide inhibitor in dialysis patients. J Am Soc Nephrol 1997;8:1437-42.
56. Marescau B, Nagels G, Possemiers I, et al. Guanidino compounds in serum and urine of nondialyzed patients with chronic renal insufficiency. Metabolism 1997;46:1024-31.
57. MacAllister RJ, Whitley GSJ, Vallance P. Effects of guanidino and uremic compounds on nitric oxide pathways. Kidney Int 1994;45:737-42.
58. Adams MR, McCredie R, Jessup W, Robinson J, Sullivan D, Celermajer DS. Oral L-arginine improves endothelium-dependent dilatation and reduces monocyte adhesion to endothelial cells in young men with coronary artery disease. Atherosclerosis 1997;129:261-9.
59. Clarkson P, Adams MR, Powe AJ, et al. Oral L-arginine improves en3 dothelium-dependent dilation in hypercholesterolemic young adults. J Clin Invest 1996;97:1989-94.
60. Baydoun AR, Emery PW, Pearson JD, Mann GE. Substrate-dependent regulation of intracellular amino acid concentrations in cultured bovine aortic endothelial cells. Biochem Biophys Res Commun 1990; 173:940-8.
61. Pollock JS, Foerstermann U, Mitchell JA, et al. Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells. Proc Natl Acad Sci U S A 1991;88:10480-4.
62. G-dimethylarginine by human endothelial cells. Endothelium 1993;1:137-40.
63. MacAllister RJ, Fickling SA, Whitley GStJ, Vallance P. Metabolism of methylarginines by human vasculature: implications for the regulation of nitric oxide synthesis. Br J Pharmacol 1994; 112:43-8.
64. Boeger RH, Bode-Boeger SM, Tsao PS, Lin PS, Chan JR, Cooke JP. The endogenous NO synthase inhibitor asymmetric dimethylarginine (ADMA) exerts pro-atherogenic effects in cultured human endothelial cells [Abstract]. Circulation 1997; 96(suppl I):I-286.
65. Azuma H, Sato J, Hamasaki H, Sugimoto A, Isotani E, Obayashi S. Accumulation of endogenous inhibitors for nitric oxide synthesis and decreased content of L-arginine in regenerated endothelial cells. Br J Pharmacol 1995;115:1001-4.
66. Adams MR, Forsyth CJ, Jessup W, Robinson J, Celermajer DS. Oral L-arginine inhibits platelet aggregation but does not enhance endothelium-dependent dilation in healthy young men. J Am Coll Cardiol 1995;26:1054-61.
67. MacAllister RJ, Parry H, Kimoto M, et al. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol 1996;119:1533-10.
68. Cantoni GL. Biological methylation: selected aspects. Annu Rev Biochem 1975;44:431-55.